# Lyell Immunopharma Inc. (LYEL) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $14.37, market value $352 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Lyell Immunopharma Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 13042.2×**. Each dollar of revenue is priced at 13042.2×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 1.4×**. The shares trade at 1.4× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -38.0%** (5-yr avg -40.2%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -110.6%**. Return on equity is negative because earnings are negative.
- **Return on assets: -73.1%**. Each dollar of assets produces -73.1% of profit.

## Growth
- **Revenue growth (1 yr): -41.0%** (3-yr -92.5%/yr, 5-yr -65.9%/yr). Revenue fell 41.0% over the last year, against -65.9% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 38.8%**. Earnings per share rose 38.8%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Current ratio: 5.28** (quick 5.28). Current assets cover the next year's liabilities 5.28 times.
- **Altman Z-score: 1.45**. A Z-score of 1.45 is in the distress zone, a signal to examine the balance sheet closely.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Lyell Immunopharma Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 22.6%** (YTD -53.3%, 3-mo 20.1%). The shares are up 22.6% over twelve months including dividends.
- **From 52-week high: -68.1%** (25.3% above the low). Trading 68% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 49**. An RSI of 49 is neutral.
- **Beta (1 yr): 1.63** (volatility 82%). Beta of 1.63 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=LYEL · Page: https://foliofundamentals.com/stocks/lyel

Not investment advice.